Cars.com
CARS
Lantheus
LNTH
Halozyme Therapeutics
HALO
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
Collegium Pharmaceutical
COLL
US Stock MarketDetailed Quotes
ADVM Adverum Biotechnologies
- 4.7100
- +0.3100+7.05%
Close Feb 28 16:00 ET
- 4.9000
- +0.1900+4.03%
Post 20:01 ET
97.98MMarket Cap-0.79P/E (TTM)
4.7500High4.0800Low270.09KVolume4.3600Open4.4000Pre Close1.23MTurnover2.07%Turnover RatioLossP/E (Static)20.80MShares20.900052wk High0.68P/B61.54MFloat Cap3.520052wk Low--Dividend TTM13.07MShs Float624.8000Historical High--Div YieldTTM15.23%Amplitude3.5200Historical Low4.5440Avg Price1Lot Size
Adverum Biotechnologies News
Analysts' Top Healthcare Picks: Adverum Biotechnologies (ADVM), Gilead Sciences (GILD)
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Cuts Target Price to $16
Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
H.C. Wainwright Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $30
Buy Rating on Adverum Biotechnologies: Ixo-vec's Promising Potential in Transforming Wet AMD Treatment
Adverum Biotechnologies Analyst Ratings
RBC Capital Initiates Adverum Biotechnologies(ADVM.US) With Hold Rating, Announces Target Price $10
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
A Quick Look at Today's Ratings for Adverum Biotechnologies(ADVM.US), With a Forecast Between $10 to $30
Buy Rating on Adverum Biotechnologies Driven by Ixo-vec's Promising Data and Potential Impact on AMD Treatment
Adverum Biotechnologies (ADVM) Gets a Buy From TD Cowen
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Chardan Capital Upgrades Adverum Biotechnologies(ADVM.US) to Buy Rating
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $20
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)